Skip to main content
SpringerLink
Log in

Assessment of the Risk for Venous Thromboembolism Among Users of Hormone Replacement Therapy

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Although hormone replacement therapy (HRT) provides health benefits, concerns about harmful effects have been raised, including an increased risk of venous thromboembolism. The purpose of this review is to assess the risk for venous thromboembolism associated with HRT.

Data searches involved the MEDLINE database from January 1982 to December 1997, and bibliographies of retrieved articles. Seven case-control studies and 1 prospective cohort study considering venous thromboembolism as the outcome of interest were selected and rated according to methodological criteria. Results of case-controls studies were pooled to determine an overall estimate.

The pooled risk ratio (95% confidence interval) for venous thromboembolism among current users of HRT compared with non-users (never-users and past-users combined) was 2.1 (1.4 to 3.0) in the case-control studies (n = 7). Based on one prospective cohort study, the risk of primary pulmonary embolism associated with HRT was 2.1 (1.2 to 3.8). No association was found with past use of HRT. The risk of venous thromboembolism was higher within the first year of treatment. There was no strong evidence for a dose-response relationship with estrogen. No striking difference in risk of venous thromboembolism was observed between unopposed and opposed regimens. The small number of women using transdermal estrogen therapy precluded any firm conclusions about the impact of the route of estrogen administration.

Current use of oral estrogen as HRT is associated with a 2- to 3-fold increased risk of venous thromboembolism. However, the absolute risk remains low, and these findings need to be weighed against the potential benefits of treatment. Whether transdermal estrogen therapy is safe with respect to venous thromboembolism has yet to be adequately investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lichtman R. Perimenopausal hormone replacement therapy: review of the literature. J Nurse Midwifery 1991; 36: 30–48

    Article  PubMed  CAS  Google Scholar 

  2. Barzel U. Estrogen in the prevention and treatment of post-menopausal osteoporosis: a review. Am J Med 1988; 85: 847–50

    Article  PubMed  CAS  Google Scholar 

  3. Felson DT, Zhang Y, Hannan MT, et al. The effect of post-menopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6

    Article  PubMed  CAS  Google Scholar 

  4. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9

    PubMed  CAS  Google Scholar 

  5. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75Suppl. 4: 18S–25

    PubMed  CAS  Google Scholar 

  6. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–7

    Article  PubMed  CAS  Google Scholar 

  7. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Heath Study. N Engl J Med 1991; 325: 756–62

    Article  PubMed  CAS  Google Scholar 

  8. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208

    Article  Google Scholar 

  9. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61

    Article  PubMed  CAS  Google Scholar 

  10. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  11. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75

    Article  PubMed  CAS  Google Scholar 

  12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047–59

    Article  Google Scholar 

  13. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1589–92

    Article  Google Scholar 

  14. The Coronary Drug Project Research Group. The coronary drug project: initial findings leading to modifications of its research protocol. JAMA 1970; 214: 1303–13

    Article  Google Scholar 

  15. Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15–9

    Article  Google Scholar 

  16. Petitti DB, Wingerd J, Pellegrin F, et al. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150–4

    Article  PubMed  CAS  Google Scholar 

  17. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275–82

    Article  PubMed  CAS  Google Scholar 

  18. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80

    Article  PubMed  CAS  Google Scholar 

  19. Daly E, Vessey MP, Painter R, et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy [letter]. Lancet 1996; 348: 1027

    Article  PubMed  CAS  Google Scholar 

  20. Jick H, Derby LE, Wald Myers M, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3

    Article  PubMed  CAS  Google Scholar 

  21. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–7

    Article  PubMed  CAS  Google Scholar 

  22. Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157: 1522–30

    Article  PubMed  CAS  Google Scholar 

  23. Perez-Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796–800

    Article  PubMed  CAS  Google Scholar 

  24. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med 1997; 126: 532–8

    PubMed  CAS  Google Scholar 

  25. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997; 127: 531–7

    PubMed  CAS  Google Scholar 

  26. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1–30

    PubMed  CAS  Google Scholar 

  27. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121–45

    Article  PubMed  CAS  Google Scholar 

  28. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74–9

    Article  PubMed  CAS  Google Scholar 

  29. Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy [letter]. JAMA 1997; 278: 477

    Article  PubMed  CAS  Google Scholar 

  30. Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739–42

    Article  PubMed  CAS  Google Scholar 

  31. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia. Thromb Haemost 1996; 76 (Pt 1): 651–2

    PubMed  CAS  Google Scholar 

  32. Caine YG, Bauer KA, Barzegar S. Coagulation activation following estrogen administration in postmenopausal women. Thromb Haemost 1992; 68: 392–5

    PubMed  CAS  Google Scholar 

  33. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–8

    Article  PubMed  CAS  Google Scholar 

  34. Conard J, Samama M, Basdevant A, et al. Differential ATIII response to oral and parenteral administration of 17-β estradiol [letter]. Thromb Haemost 1983; 49: 245

    Google Scholar 

  35. De Lignières B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536–41

    Article  PubMed  Google Scholar 

  36. The Writing group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double blind, placebo-controlled study. Thromb Haemost 1996; 75: 476–80

    Google Scholar 

  37. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–90

    Article  PubMed  CAS  Google Scholar 

  38. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Chest Diseases, Hôpital de la Cavale Blanche, Brest, France

    Emmanuel Oger

  2. INSERM Cardiovascular Epidemiology Unit U258, Hôpital Broussais, 96, Rue Didot, 75674, Paris Cedex 14, France

    Pierre-Yves Scarabin

Authors
  1. Emmanuel Oger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre-Yves Scarabin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Yves Scarabin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oger, E., Scarabin, PY. Assessment of the Risk for Venous Thromboembolism Among Users of Hormone Replacement Therapy. Drugs & Aging 14, 55–61 (1999). https://doi.org/10.2165/00002512-199914010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199914010-00004

Keywords

Search

Navigation